Trump Weighs Blocking Exxon Investment as Venezuela Deemed “Uninvestable” 
AFT Leaves X Over AI-Generated Images of Minors 
Coca-Cola Shelves Costa Coffee Sale After Low Private Equity Offers 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
U.S. Government Invests $1 Billion in L3Harris Rocket Motor Business to Secure Missile Supply Chain 
Alphabet Stock Poised for Growth as Bank of America Sees Strong AI Momentum Into 2026 
BESI Reports Strong Q4-25 Orders Surge Driven by Data Center and Hybrid Bonding Demand 
AbbVie Commits $100 Billion to U.S. Investment in Drug Pricing Deal With Trump Administration 
BlueScope Steel Announces A$1 Special Dividend After Asset Sales 
Saks Global Files for Bankruptcy Protection Amid Mounting Luxury Retail Pressures 
Trump Administration Approves Nvidia H200 AI Chip Sales to China Under New Export Rules 
Tesla, EEOC Move Toward Mediation in Racial Harassment Lawsuit 
Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network 
Taiwan Issues Arrest Warrant for OnePlus CEO Over Alleged Illegal Recruitment Activities 
Netflix Plans All-Cash Bid for Warner Bros Discovery Studios Amid Intense Hollywood Takeover Battle 
Trump Pushes Tech Giants to Absorb AI Data Center Power Costs, Citing Microsoft Changes 
Nvidia Denies Upfront Payment Requirement for H200 AI Chips Amid China Export Scrutiny 
NEWARK, Calif., March 30, 2017 -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company developing therapies for specialty and orphan diseases with high unmet medical need, today announced that management will provide a corporate overview at the H.C. Wainwright & Co. 1st Annual NASH Investor Conference, being held April 3, 2017 at the St. Regis Hotel in New York City, and the BioCentury Future Leaders in the Biotech Industry Conference, being held April 7 at the Millennium Broadway Hotel & Conference Center in New York City.
| 1st Annual NASH Investor Conference | |
| Date: | Monday, April 3 |
| Time: | 11:40am Eastern Time |
| Location: | St. Regis Hotel, New York City |
| Webcast: | http://ir.cymabay.com/events |
| BioCentury Future Leaders in the Biotech Industry Conference | |
| Date: | Friday, April 7 |
| Time: | 1:30pm Eastern Time |
| Location: | Millennium Broadway Hotel & Conference Center, New York City, NY |
About CymaBay
CymaBay Therapeutics, Inc. (CBAY) is a clinical-stage biopharmaceutical company focused on developing therapies to treat metabolic diseases with high unmet medical need, including serious rare and orphan disorders. Seladelpar is a potent, selective, orally active PPARδ agonist. A Phase 2 study of seladelpar in patients with mixed dyslipidemia established that it has an anti-atherogenic lipid profile. CymaBay has completed Phase 2 studies for seladelpar in subjects with primary biliary cholangitis and homozygous familial hypercholesterolemia, establishing proof-of-concept in both indications. Arhalofenate, CymaBay’s other product candidate, is a potential Urate-Lowering Anti-Flare Therapy that has completed five Phase 2 studies in subjects with gout. Arhalofenate has been found to reduce painful flares in joints while at the same time lowering serum uric acid by promoting excretion of uric acid by the kidney. This dual action addresses both the signs and symptoms of gout while managing the underlying pathophysiology of hyperuricemia. Arhalofenate has been licensed in the U.S. to Kowa Pharmaceuticals America, Inc. CymaBay retains full development and commercialization rights for arhalofenate outside the U.S.
For additional information about CymaBay visit www.cymabay.com.
Contact: Sujal Shah CymaBay Therapeutics, Inc. (510) 293-8800 [email protected] Hans Vitzthum LifeSci Advisors, LLC 212-915-2568 [email protected]
